Natco Pharma Limited
Natco Pharma Limited is a Public Non-govt company company incorporated in 1981 and based in Telangana, India. Natco Pharma Limited operates in Manufacture of pharmaceuticals, medicinal chemicals and botanical products (NIC 24230) with authorized capital of ₹40.00 Cr and paid-up capital of ₹36.51 Cr. For 2025-26, the company reported revenue of ₹3594.60 Cr and profit after tax of ₹1281.50 Cr. The board has 3 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
NATCO PHARMA LIMITED is the legal entity of Natco Pharma.
Quick facts
Directors
3 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +8d | filed |
| MGT-7 | FY2024-25 | 22 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 22 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Natco Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 716257354 | State Bank of India(Bank) | ₹9.52 Cr | 12 Mar 2023 | Open |
| 970663427 | Axis Bank Ltd(Bank) | ₹13.67 Cr | 27 Jan 2022 | Satisfied |
| 585655271 | Axis Bank Ltd(Bank) | ₹21.87 Cr | 04 Jul 2019 | Open |
| 667542017 | HDFC Bank Ltd(Bank) | ₹4.98 Cr | 27 Jan 2022 | Open |
Charge IDs, lenders & amounts for Natco Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2025-26 | — | ||||
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2021-22 | — |
Detailed Financials
4 FYs| Line item | 2025-26 | 2023-24 | 2022-23 | 2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2025-26 | +1.0% | +27.0% | — | |
| Profit after Tax2025-26 | -9.0% | +794.0% | — | |
| Net Worth2023-24 | +48.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2021-22 | +7.86% | — | +3.32% | +2.79% | — | |||
| 2022-23 | +27.09% | +32.98% | +13.55% | +11.82% | — | |||
| 2023-24 | +36.62% | +51.81% | +23.37% | +19.94% | — | |||
| 2025-26 | +35.65% | +0.72% | — | — | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 2,54,48,045 | 66.23% |
| Institutional Investors | 3 | 59,67,566 | 15.53% |
| Public & Others | 59 | 70,09,928 | 18.24% |
Promoter, institutional & public holding for Natco Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
5 peersTop 10 in Manufacture of pharmaceuticals, medicinal chemicals and botanical products
by healthView all ›Events & timeline
4External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.